Search for:

In brief

In October 2023, the Health Sciences Authority (HSA) participated in a one-week INTERPOL-led, internet-based operation involving 89 member countries targeting the sale of illegal health products.

The HSA announced that it removed over 4,600 listings of illegal health products from local e-commerce and social media platforms and seized more than 60,000 units of illegal health products at the Singapore Customs during a week of intensified surveillance from 3 to 10 October 2023.


Key takeaways

  • Sellers and suppliers of health products should note that anyone who supplies in Singapore prescription medicines and medical devices, and/or health products that are adulterated, counterfeit or tampered with may face a fine of up to SGD 100,000 and/or imprisonment for up to three years.

In depth

On 31 October 2023, the HSA announced that 4,681 product listings of illegal health products were removed from e-commerce and social media platforms, and 60,372 units of illegal health products were seized during a one-week intensified enforcement action as part of Operation Pangea.

The removed product listings were mainly lifestyle health products, such as sexual enhancement or male vitality products, aesthetic enhancement products (dermal fillers, Botulinum toxin, sutures and placenta injectables), contraceptives, topical creams or ointments for skin allergy, and weight loss products. The seized products consisted of various illegal and adulterated health products, such as sexual enhancement products, sedatives, herbal supplements and pain management products. 

The HSA has advised members of the public to avoid buying prescription-only medicines (such as erectile dysfunction medicines, weight loss medicines and DIY aesthetic beauty injectable kits) and be wary of purchasing health products (such as health supplements and cosmetic products) online. Additionally, extra caution should be exercised with regard to health products that promise quick and miraculous results or carry exaggerated claims (such as “100% safe”; “no side effects”; “quick effects”; or “scientifically proven”). These are products that may be adulterated with potent medicinal ingredients or prescription-only products that should be administered only by qualified medical practitioners. Given that they have not been evaluated and/or approved by the HSA, there is no assurance of their safety, quality and efficacy. If used or administered incorrectly, serious adverse reactions may ensue.

Therefore, the HSA recommends that health products only be purchased online from reputable retailers’ websites or those with an established retail presence in Singapore. 

Sellers and suppliers are also reminded not to sell prescription medicines and medical devices on e-commerce platforms, or health products that are adulterated or bear misleading claims.

The full HSA announcement may be found here.

Author

Andy Leck is the head of the Intellectual Property and Technology (IPTech) Practice Group and a member of the Dispute Resolution Practice Group in Singapore. He is a core member of Baker McKenzie's regional IP practice and also leads the Myanmar IP Practice Group. Andy is recognised by reputable global industry and legal publications as a leader in his field. He was named on "The A-List: Singapore's Top 100 lawyers" by Asia Business Law Journal 2018. In addition, Chambers Asia Pacific notes that Andy is "a well-known IP practitioner who is highlighted for his record of handling major trade mark litigation, as well as commercial exploitation of IP rights in the media and technology sectors. He's been in the industry for a long time and has always been held in high regard. He is known to be very fair and is someone you would like to be in the trenches with you during negotiations." Furthermore, Asian Legal Business acknowledges Andy as a leading practitioner in his field and notes that he “always gives good, quick advice, [is] client-focused and has strong technical knowledge for his areas of practice.” Andy was appointed by the Intellectual Property Office of Singapore (IPOS) as an IP Adjudicator to hear disputes at IPOS for a two-year term from April 2021. He has been an appointed member of the Singapore Copyright Tribunal since May 2010 and a mediator with the WIPO Arbitration and Mediation Center. He is also appointed as a Notary Public & Commissioner for Oaths in Singapore. He previously served on the International Trademark Association’s Board of Directors and was a member of the executive committee.

Author

Ren Jun Lim is a principal with Baker McKenzie Wong & Leow. He represents local and international clients in both contentious and non-contentious intellectual property matters. He also advises on a full range of healthcare, as well as consumer goods-related legal and regulatory issues. Ren Jun co-leads Baker McKenzie Wong & Leow's Healthcare as well as Consumer Goods & Retail industry groups. He sits on the Law Society of Singapore IP Committee and on the Executive Committee of the Association of Information Security Professionals. He is also a member of the Vaccines Working Group, Singapore Association of Pharmaceutical Industries, a member of the International Trademark Association, as well as a member of the Regulatory Affairs Professionals Association. Ren Jun is ranked in the Silver tier for Individuals: Enforcement and Litigation and Individuals: Prosecution and Strategy, and a recommended lawyer for Individuals: Transactions by WTR 1000, 2020. He is also listed in Asia IP's Best 50 IP Expert, 2020, recognised as a Rising Star by Managing IP: IP Stars, 2019 and one of Singapore's 70 most influential lawyers aged 40 and under by Singapore Business Review, 2016. Ren Jun was acknowledged by WTR 1000 as a "trademark connoisseur who boasts supplementary knowledge of regulatory issues in the consumer products industry." He was also commended by clients for being "very responsive to enquiries and with a keen eye for detail, he is extremely hands-on. His meticulous and in-depth approach to strategising is key to the excellent outcomes we enjoy."

Write A Comment